The license and supply agreement enables ResearchDx to provide high-throughput exosome isolation, biomarker discovery and diagnostics development services to its customers in the US, using Inoviq’s EXO-NET exosome capture technology
ResearchDX partners with Inoviq for EXO-NET technology. (Credit: Louis Reed on Unsplash)
US-based contract diagnostics organisation (CDO) ResearchDx has signed a license and supply agreement with Australian exosome solutions and precision diagnostics provider Inoviq.
Under the terms of the agreement, ResearchDx will use Inoviq’s EXO-NET technology to provide exosome isolation, biomarker discovery and diagnostics services in the US.
The partnership builds on ResearchDx’s previous joint marketing agreement for Inoviq’s EXO-NET exosome capture technology and Promega Nucleic Acid purification systems.
The latest collaboration combines ResearchDx’s expertise in developing and validating IVD diagnostics with Inoviq’s exosome capture technology, tools and expertise in diagnostics.
ResearchDx will offer a wide range of contract research services to its academic, biotech and pharmaceutical customers in the US, using Inoviq’s EXO-NET exosome capture tools.
Inoviq CEO Leearne Hinch said: “ResearchDx is a key part of our strategy to expand INOVIQ’s EXO-NET exosome services in the USA. It builds on our established and successful contract research relationship with them for the development of our SubB2M tests.
“By partnering with ResearchDx, US customers now have access to a full range of EV isolation, biomarker discovery and diagnostic development services by a CAP and CLIA accredited Contract Research Organisation.
“This is an important, strategic move that enables us to provide high-quality EXO-NET services to customers in the US, Australia and elsewhere, expanding our revenue generation opportunities for EXO-NET.”
ResearchDx is a full-service CDO engaged in the development of companion diagnostics (CDx), in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs).
With expertise in the design, development, validation, and registration of diagnostics, the company operates under an integrated diagnostics business model.
ResearchDx previously evaluated Inoviq’s EXO-NET technology for both manual and automated extracellular vesicle (EV) isolation.
Under the partnership, the two companies will leverage their combined exosome and IVD diagnostics development expertise to advance exosome-based diagnostics development.
ResearchDx principal and co-founder Mat Moore said: “We look forward to offering EXO-NET enabled EV isolation, biomarker discovery and diagnostic development services in our Development, GLP, and CLIA accredited laboratories to US customers.
“EXO-NET is a powerful exosome isolation platform that has the potential to enable earlier disease detection and the more accurate monitoring of disease progression and response to therapy.”